Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug used primarily as an intravesical (bladder) instillation for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The formulation typically includes bupivacaine, a local anesthetic that blocks nerve conduction to provide pain relief; triamcinolone, a synthetic corticosteroid with anti-inflammatory properties; and heparin, an anticoagulant that also stabilizes the bladder mucosa and may reduce inflammation. This combination aims to provide both immediate symptomatic relief (via anesthesia) and longer-term reduction in bladder inflammation. It is not marketed under a unique brand name but is compounded for use in urology clinics. Clinical studies have shown it provides significant improvement in symptoms such as pain, urinary frequency, and nocturia in patients with IC/BPS[1][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + triamcinolone + heparin.